All News

Charges of scientific fraud in Korea aren't likely to faze Britain's ambitious stem-cell efforts, as evidenced by plans for a £40 million lab run by the 'father' of Dolly the sheep.

Diamonds are the hardest natural substance known to man, and hard to find too. But Russian scientists say they have found a way to make prospecting for the precious mineral much easier.

"I didn't think they would be at this stage for decades, let alone within a year." Gerald Schatten, colleague of Korea's stem-cell celebrity, before scandal broke

At any given time over 1.4 million people worldwide are suffering from infections they got from their health-provider, according to the World Health Organization. Pelias AG, a newly created affiliate of Austrian biotech company Intercell AG, is hoping to raise €15 million to €20 million to make a dent in those numbers.

Cambridge University is tightening its grip on rights to intellectual property generated by staff and students after academics voted overwhelmingly to endorse new plans

A new Swedish company backed by government and business angels aims to create an entire funding ecosystem for young companies until they become ready for venture capital.

IP2IPO Group, which specialises in commercialising university technology, has made an exclusive 25-year deal with the University of Bristol to form spin-out companies from the university. Analysts greeted the deal as a boost for the company.

Microsoft is to open more research centres in Europe, in a move to step up its research collaboration and boost students' interest in the technology field.

What are stem cells, what could they do - and why are investors wary of putting their money in them? A lay guide to the technology

Two New Year's resolutions for the governments around the world that have managed to gum up the economic machinery behind technological development.

Investing in technology that's a few years from commercialisation can be tricky. Lori Valigra finds out how some venture capitalists sort the wheat from the chaff.

The European Commission's Clinical Trials Directive was meant to make trials more simple. But it looks as if the effect has been to stop many trials taking place at all.